BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27230580)

  • 1. Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.
    Zheng G; Xue W; Wang P; Yang F; Li B; Li X; Li Y; Yao X; Zhu F
    Sci Rep; 2016 May; 6():26883. PubMed ID: 27230580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation.
    Xue W; Yang F; Wang P; Zheng G; Chen Y; Yao X; Zhu F
    ACS Chem Neurosci; 2018 May; 9(5):1128-1140. PubMed ID: 29300091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD.
    Wang P; Fu T; Zhang X; Yang F; Zheng G; Xue W; Chen Y; Yao X; Zhu F
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2766-2777. PubMed ID: 28757337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
    Zhou Z; Zhen J; Karpowich NK; Goetz RM; Law CJ; Reith ME; Wang DN
    Science; 2007 Sep; 317(5843):1390-3. PubMed ID: 17690258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
    Zhang P; Terefenko EA; McComas CC; Mahaney PE; Vu A; Trybulski E; Koury E; Johnston G; Bray J; Deecher D
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6067-70. PubMed ID: 18951020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.
    Benson N; Snelder N; Ploeger B; Napier C; Sale H; Birdsall NJ; Butt RP; van der Graaf PH
    Br J Pharmacol; 2010 May; 160(2):389-98. PubMed ID: 20423348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
    Hudson S; Kiankarimi M; Eccles W; Mostofi YS; Genicot MJ; Dwight W; Fleck BA; Gogas K; Wade WS
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4495-8. PubMed ID: 18667309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.
    Xue W; Wang P; Tu G; Yang F; Zheng G; Li X; Li X; Chen Y; Yao X; Zhu F
    Phys Chem Chem Phys; 2018 Feb; 20(9):6606-6616. PubMed ID: 29451287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure Modeling of the Norepinephrine Transporter.
    Góral I; Łątka K; Bajda M
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.
    Paudel S; Sun N; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2018 Aug; 26(14):4127-4135. PubMed ID: 30007567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
    Zhang P; Terefenko EA; Bray J; Deecher D; Fensome A; Harrison J; Kim C; Koury E; Mark L; McComas CC; Mugford CA; Trybulski EJ; Vu AT; Whiteside GT; Mahaney PE
    J Med Chem; 2009 Sep; 52(18):5703-11. PubMed ID: 19722525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A perhaps unexpected role of norepinephrine in actions of MDMA.
    Newton TF
    Clin Pharmacol Ther; 2011 Aug; 90(2):215-6. PubMed ID: 21772299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
    Arias HR; Ortells MO; Feuerbach D
    Neurochem Int; 2013 Nov; 63(5):423-31. PubMed ID: 23917086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.
    Xue W; Wang P; Li B; Li Y; Xu X; Yang F; Yao X; Chen YZ; Xu F; Zhu F
    Phys Chem Chem Phys; 2016 Jan; 18(4):3260-71. PubMed ID: 26745505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors.
    Xu W; Gray DL; Glase SA; Barta NS
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5550-3. PubMed ID: 18805691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A second extracellular site is required for norepinephrine transport by the human norepinephrine transporter.
    Wang CI; Shaikh NH; Ramu S; Lewis RJ
    Mol Pharmacol; 2012 Nov; 82(5):898-909. PubMed ID: 22874414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER.
    Tavares AA; Barret O; Batis J; Alagille D; Koren A; Papin C; Kudej G; Nice K; Kordower JH; Cosgrove KP; Kloczynski T; Brenner E; Seibyl J; Tamagnan G
    Synapse; 2013 Jan; 67(1):30-41. PubMed ID: 23042643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling and structural analysis of nAChR variants uncovers the mechanism of resistance to snake toxins.
    Gunasekaran D; Sridhar J; Suryanarayanan V; Manimaran NC; Singh SK
    J Biomol Struct Dyn; 2017 Jun; 35(8):1654-1671. PubMed ID: 27421773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans.
    Mayer AF; Schroeder C; Heusser K; Tank J; Diedrich A; Schmieder RE; Luft FC; Jordan J
    Hypertension; 2006 Jul; 48(1):120-6. PubMed ID: 16717144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.